Approval for AKEEGATM is based on results from the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study that includes the largest cohort to date of BRCA1/2-positive patients with untreated… Read More
Gemina Laboratories and ReadyGo Diagnostics achieve mycobacterium tuberculosis diagnosis in saliva VANCOUVER, BC — Gemina Laboratories Ltd. (CSE: GLAB) (FRA:8I7), a specialist in fast, affordable, and accurate diagnostic tests, is… Read More
VANCOUVER, BC — (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to… Read More
DT-9045 is a unique drug candidate due to its competitive differentiating pharmacological features Start of Phase 1 ascending dose studies in recurrent or metastatic solid tumors with DT-9045 is expected… Read More
Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity, confirmed objective response rate (cORR) of 41.3%, median duration of response (DOR)… Read More
